In its latest quarter ending June 30, 2026, Pulmonx Corp demonstrated continued progress in commercializing its Zephyr Endobronchial Valve for severe emphysema, achieving revenue growth that contributed to reduced net losses. Despite operational improvements including enhanced gross margins and sales execution, the company remains dependent on a narrow product portfolio subject to regulatory and reimbursement uncertainties. Capital structure constraints with approximately $62 million in debt paired with $56 million in cash limit financial flexibility. Future growth hinges on expanding clinical indications, securing broader reimbursement, and scaling hospital adoption within the competitive respiratory medical devices space.